Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans

Alcohol is abused commonly, but there is no antidote for alcohol intoxication the way
naltrexone or naloxone is an antidote for opioids. A medication that has the potential to
block alcohol actions in the Central Nervous System could act as a unique medication in the
treatment of alcohol intoxication and alcoholism. This project is evaluating the
benzodiazepine partial inverse agonist, iomazenil, as an agent that could reverse alcohol's
effects on subjective intoxication, alcohol's effects on driving using a driving simulator
and on measures of electrophysiology in the laboratory in healthy subjects.

Inclusion Criteria:

- Males and females

- 21-35 years old

- Medically healthy

Exclusion Criteria:

- Under the age of 21 or greater than the age 35

- Positive pregnancy test

- History of seizures